TSRL, Inc. Market Research Report

Background

Company Overview

TSRL, Inc. is a privately held preclinical contract research organization (CRO) based in Ann Arbor, Michigan. Established in 1986, TSRL specializes in advancing early-stage drug candidates, particularly in the realm of infectious diseases, through comprehensive preclinical development services. The company's mission is to remove barriers in preclinical development by applying its knowledge, infrastructure, and partnerships to transform promising drug therapy concepts into Investigational New Drug (IND)-enabling product opportunities.

Mission and Vision

• Mission: To eliminate obstacles in preclinical development by leveraging expertise, infrastructure, and partnerships to convert promising drug therapy concepts into IND-enabling products.

• Vision: Focused on building, innovating, collaborating, and committing to:

• Build: Expand on a strong foundation in early-stage drug discovery to assist promising compounds in reaching clinical development.

• Innovate: Collaborate with industry and academia to advance preclinical drug assets to IND.

• Collaborate: Integrate people, processes, and partnerships to move ideas forward.

• Commit: Take an active stake in success through collaborative investment and meaningful engagement.

Key Strategic Focus

Core Objectives

TSRL's strategic focus centers on providing integrated support across various preclinical development stages, including:

• Formulation Development: Enhancing solubility, stability, and delivery methods.

• Bioanalysis: Conducting high-sensitivity drug quantification using HPLC and LC-MS/MS.

• Pharmacokinetics (PK), Absorption, Distribution, Metabolism, and Excretion (ADME), and Toxicology: Assessing compound behavior and safety profiles.

• Drug Delivery Technology: Developing novel delivery systems, including MicroArray Patch (MAP) technology.

• Strategic Consulting: Offering guidance to close knowledge gaps and align with regulatory needs.

Areas of Specialization

TSRL specializes in preclinical development with an emphasis on drug delivery, particularly targeting infectious diseases such as influenza, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), poxvirus, human papillomavirus (HPV), adenovirus, and RNA viruses.

Key Technologies Utilized

• Hydrophilic Solubilization Technology (HST): A water-soluble pharmaceutical coating based on lecithin and gelatin that increases the dissolution rate of poorly soluble drugs, improving oral bioavailability.

• Lipophilic Solubilization Technology (LST): A microemulsion drug delivery system that enhances the bioavailability of water-insoluble drugs over other microemulsion systems.

Primary Markets Targeted

TSRL primarily targets pharmaceutical, biotechnology, and academic sectors, focusing on early-stage drug programs, particularly those developing therapeutics for infectious diseases.

Financials and Funding

Funding History

TSRL has secured substantial non-dilutive funding to advance its portfolio and expand partnerships. Notably, the company has been awarded multiple Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), including:

• 2024: A Phase II SBIR grant of $1.3 million for the development of a novel, self-applied MicroArray Patch (MAP) of zanamivir for influenza treatment.

• 2023: A Phase II SBIR grant of $4.95 million for the development of methionyl-tRNA synthetase inhibitors for Gram-positive bacterial infections.

• 2022: A Phase II SBIR grant of $1.7 million for the development of synthetic high-density lipoproteins for the treatment of infection complications such as sepsis.

Utilization of Capital

The capital from these grants is intended to support the continued development of TSRL's lead candidates, including the MAP technology for influenza treatment and novel antibiotics targeting multi-drug resistant infections.

Pipeline Development

Key Pipeline Candidates

• MRS-2541: A novel small-molecule antibiotic targeting methionyl-tRNA synthetase, with potential applications in treating acute bacterial skin and skin structure infections (ABSSSIs).

• Microneedle Patch (MAP) of Zanamivir: A transdermal delivery system for zanamivir, aiming to provide a painless and convenient alternative to inhalation therapy for influenza treatment.

Stages of Development

Both candidates are in the preclinical development stage, with ongoing studies to assess pharmacokinetics, safety, and efficacy.

Target Conditions

• MRS-2541: ABSSSIs caused by Gram-positive bacteria.

• MAP of Zanamivir: Influenza A and B infections.

Anticipated Milestones

TSRL aims to advance these candidates toward clinical trials, with IND applications anticipated following successful preclinical evaluations.

Technological Platform and Innovation

Proprietary Technologies

• Hydrophilic Solubilization Technology (HST): Enhances the dissolution rate of poorly soluble drugs, improving oral bioavailability.

• Lipophilic Solubilization Technology (LST): A microemulsion system that increases the bioavailability of water-insoluble drugs.

Significant Scientific Methods

• Formulation Development: Utilizing HST and LST to optimize drug delivery.

• Bioanalysis: Employing HPLC and LC-MS/MS for precise drug quantification.

• PK/ADME and Toxicology Studies: Conducting in vitro and in vivo assessments to understand compound behavior and safety profiles.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, TSRL's comprehensive preclinical services suggest the potential integration of advanced data analysis techniques to support drug development.

Leadership Team

Key Executives

• Dr. Elke Lipka, PhD, MBA: President and Chief Executive Officer. Dr. Lipka has over 20 years of experience in pharmaceutical R&D, including roles at Parke-Davis, Pfizer, and Esperion Therapeutics. She has secured nearly $20 million in non-dilutive funding to advance TSRL’s portfolio.

• Ms. Dawn Reyna: Chief Operating Officer. Ms. Reyna joined TSRL in 2007 and has over 18 years of research and quality assurance expertise, having managed GLP-compliant quality systems at Pfizer and MPI Research.

Board Members

• Gerry Cox: Co-Founder of Velesco Pharmaceutical, appointed to TSRL's Board of Directors in August 2025. Mr. Cox brings over 30 years of biopharma leadership experience.

Competitor Profile

Market Insights and Dynamics

The preclinical CRO market is characterized by a growing demand for specialized services that accelerate drug development, particularly in the infectious disease sector. The increasing prevalence of multi-drug resistant infections and the need for innovative drug delivery systems drive the market's expansion.

Competitor Analysis

• Velesco Pharmaceutical: Based in Wixom, Michigan, Velesco focuses on early-phase pharmaceutical development and consulting. In October 2021, Velesco was acquired by Pace Analytical Life Sciences.

• Ash Stevens Inc.: A contract development and manufacturing organization specializing in the development and manufacturing of active pharmaceutical ingredients.

• WuXi AppTec: A global company offering a broad range of services to support the pharmaceutical, biotechnology, and medical device industries.

Strategic Collaborations and Partnerships

TSRL collaborates with academic institutions and industry partners to advance its drug development programs. Notably, the company has been awarded multiple NIH grants to support the development of innovative therapies.

Operational Insights

TSRL's 7,200 sq. ft. facility includes 5,000 sq. ft. of wet lab space, equipped for analytical chemistry, formulation, cell culture, and in vivo testing. This infrastructure supports a comprehensive range of preclinical services, providing a competitive edge in the market.